NFKB1 and cardiac hypertrophy: Some studies have suggested that the protective effect of ASIV against cardiac hypertrophy is related to the regulation of cardiac-related signaling pathways, such as inhibition of the TLR4/NF-κB signaling pathway and the Ca2+/CaN signaling pathway and regulation of NF-κB/PGC-1α signaling-mediated energy biosynthesis [18, 19, 23, 24].